KRAS mutations, such as G12D, G12V, and G12R, confer resistance to guanosine triphosphate (GTP) hydrolysis, leading to the constitutive activation of KRAS and downstream signaling pathway RAF-MEK-ERK and PI3K-AKT-MTOR that support tumor proliferation [145]. This evidence concerns the gene KRAS and neoplasm.